Skip to main content

Advertisement

You are viewing the new article page. Let us know what you think. Return to old version

Erratum | Open | Published:

Erratum: Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?

The original article was published in Journal of Neuroinflammation 2014 11:198

Erratum

After publication of our article [1], it came to our attention that we had erroneously stated that the IVIG product NewGam was produced by Sutter Health. However, Octapharma is the manufacturer of NewGamTM and Sutter Health is the sponsor of the clinical trial. Therefore the following sentence on page 2 of the original manuscript [1] is incorrect: "The effects of Sutter Health's IVIG NewGamTM are also being examined in individuals with mild cognitive impairment (MCI) [33], thought to be the transitional state between the cognitive changes of normal aging and very early dementia [34]." This sentence should read as follows: “The effects of Octapharma's IVIG NewGamTM are also being examined in individuals with mild cognitive impairment (MCI) [33], thought to be the transitional state between the cognitive changes of normal aging and very early dementia [34].”

Reference

  1. 1.

    Loeffler DA. Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered? J Neuroinflammation. 2014;11:198.

Download references

Author information

Correspondence to David A Loeffler.

Additional information

Competing interests

The author declares that he has no competing interests.

The online version of the original article can be found under doi:10.1186/s12974-014-0198-z.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark